Showing results (1-10 of 111) with videos related to
Sort By:
Pageof 12
Current Opinion in Hematology|February 2, 2023
Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemiaAndrew M BrunnerCurrent Problems in Cancer|January 4, 2022
Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS)Michael Mann, Andrew M BrunnerCurrent Hematologic Malignancy Reports|May 24, 2020
Novel Therapies in the Treatment of Adult Acute Lymphoblastic LeukemiaAlexander Gavralidis, Andrew M BrunnerHematology/Oncology Clinics of North America|February 25, 2020
Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical OpportunityAndrew M Brunner, David P SteensmaClinical Lymphoma, Myeloma & Leukemia|August 27, 2022
SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic SyndromesBrandon J Aubrey, Andrew M BrunnerClinical Advances in Hematology & Oncology : H&O|May 10, 2018
Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approachesAndrew M Brunner, David P SteensmaBlood Advances|February 10, 2022
Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?Andrew M Brunner, Geoffrey Fell, David P SteensmaOncotargets and Therapy|June 22, 2018
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AMLEvan C Chen, Amir T Fathi, Andrew M BrunnerAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencingTimothy A Graubert, Andrew M Brunner, Amir T FathiExpert Review of Anticancer Therapy|December 18, 2020
TIM-3 pathway dysregulation and targeting in cancerAmer M Zeidan, Rami S Komrokji, Andrew M BrunnerPageof 12